Analyst Reports

Mitigating Security Challenges in a Rapidly Changing IT Environment

Mitigating Security Challenges in a Rapidly Changing IT Environment

Download this analyst report to see what IDC's Reseach Vice President of Security Products, Charles Kolodgy, has to say about how to secure Rapidly changing IT environments.

Gartner: MarketScope for Vulnerability Assessment 2013

Gartner: MarketScope for Vulnerability Assessment 2013

For the 4th Consecutive year, Rapid7 rates "Strong positive" - the highest possible rating. Find out how Vulnerability Assessment solutions can benefit you and why Gartner gives Rapid7 Nexpose top marks.

451 Research: Rapid7 releases ControlsInsight and UserInsight monitoring and analytics products

451 Research: Rapid7 releases ControlsInsight and UserInsight monitoring and analytics products

Read the 451 Research product review on Rapid7's two new products, ControlsInsight and UserInsight.

IDC: Gap Analysis of Revenue Forecast and Full Deployment Revenue for the Device Vulnerability Assessment Market

IDC: Gap Analysis of Revenue Forecast and Full Deployment Revenue for the Device Vulnerability Assessment Market

Tens of billions of dollars a year are spent on information technology (IT) security, and this amount continues to grow.

IDC Private Vendor Watchlist Profile on Rapid7

IDC Private Vendor Watchlist Profile on Rapid7

This IDC Vendor Profile analyzes Rapid7 and reviews key success factors: market potential, technology/solution, corporate strategy, force multipliers, and customers. Leveraging IDC's expert understanding of the competitive landscape and future outlook, this document highlights company and market information.

Forrester Wave 2010 for Vulnerability Management

Forrester Wave 2010 for Vulnerability Management

Rapid7 has been recognized as a "Leader" by Forrester Research, Inc. in their "The Forrester Wave: Vulnerability Management, Q2 2010" report.  Rapid7 and its flagship product Nexpose® obtained scores of three or higher in every evaluated category, including being the only vendor to receive the highest possible rating of five in application-level vulnerability management.

Frost & Sullivan Strategy Report

Frost & Sullivan: Product Line Strategy of the Year Award

Rapid7 received Frost & Sullivan’s "2010 Product Line Strategy of the Year Award" in vulnerability management. According to the full report and analysis of the vulnerability management market by Frost & Sullivan, which included in-depth interviews of customers, partners and vendors, this honor recognizes the Company's innovative vulnerability management solutions, impressive market growth and continued dedication to leading the vulnerability management field.

The 451 Group: Metasploit Pro for the enterprise

The 451 Group: Metasploit Pro for the enterprise

Recently leading analyst firm The 451 Group published a report titled "Rapid7 presents penetration testing to the enterprise with Metasploit Pro release". Covering the Metasploit Pro release, The 451 Group made a number of market observations:

  • “We like the teaming features of Metasploit Pro and suspect that the ability to collaboratively work on testing projects will likely be an attractive enticement for large organizations with disparate follow-the-sun testing teams.”
  • “…there are obvious benefits to combining both Metasploit Pro and the company's flagship Nexpose vulnerability management product…”
  • “…vendors like Core and Immunity might see the penetration-testing space become very crowded, very quickly.”

The MarketScope is copyrighted February 17, 2010 by Gartner, Inc. and is reused with permission. The MarketScope is an evaluation of a marketplace at and for a specific time period. It depicts Gartner's analysis of how certain vendors measure against criteria for that marketplace, as defined by Gartner. Gartner does not endorse any vendor, product or service depicted in the MarketScope, and does not advise technology users to select only those vendors with the highest rating. Gartner disclaims all warranties, express or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.